Kidney cancer: post-surgery sorafenib
0 Visualizações
• 06/26/23
0
0
Embutir
administrator
Assinantes
Tim Eisen, MBBChir, PhD, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, describes the rationale and methodology behind the SORCE trial (NCT00492258) and what have we learned at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
Mostre mais
Comentários do Facebook
SORT BY-
Melhores Comentários
-
Últimos Comentários